Groundbreaking FDA and NMPA Approval Opens Path for IASO208 CAR-T Therapy in Global Clinical Trials

IASO Bio Propels CAR-T Therapy Advancement

IASO Biotechnology, commonly referred to as IASO Bio, has made significant strides in the biopharmaceutical landscape with the recent approval of its Investigational New Drug (IND) application for IASO208. This groundbreaking therapy, aimed at treating relapsed and refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), is the first lentiviral-vector-based in vivo CAR-T product from China to gain clearance from the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China.

In a pivotal step forward, IASO Bio’s platform, known as InTelliCAR™, has reached a remarkable milestone. The approval by the NMPA comes on the heels of the FDA’s implicit clearance of IASO208, further solidifying IASO's commitment to advancing synchronously in both the U.S. and Chinese markets. The IND approval marks a significant marker in the course of clinical research, ultimately opening doors for expanded global development and deployment of cell therapies.

The IND approval is also a testament to the efficacy of the InTelliCAR™ platform. The technology underpins a portfolio of innovative CAR-T product candidates covering not only hematologic malignancies but also autoimmune conditions and solid tumors. The data collected from investigator-initiated trials conducted in China will directly support the upcoming Phase Ib study launching in the United States.

The Phase Ib clinical study will evaluate the safety and preliminary efficacy of IASO208 among adult patients suffering from R/R B-cell malignancies. Importantly, the novel treatment approach requires no conventional apheresis or lymphodepleting conditioning, representing a significant step forward in patient convenience. Instead, patients will receive a single intravenous infusion of IASO208. Initial studies have already set the stage for a promising future; preliminary data indicates both favorable tolerability and considerable anti-tumor responses in the trial participants.

Currently, 11 patients have been enrolled in the ongoing trial, and encouraging early results from this open-label, single-arm study have piqued interest within the medical community. These early findings will be presented during an oral session at the 2026 American Society of Hematology (ASH) Annual Meeting, showcasing the potential of IASO208 in combating challenging hematologic malignancies.

Insights from IASO Bio's Leadership

Jinhua Zhang, the Founder and Chief Executive Officer of IASO Bio, highlighted the monumental nature of this dual approval. She affirmed, “The approval of the China IND for IASO208 is another milestone for IASO's proprietary in vivo CAR-T platform, InTelliCAR™, following our receipt of FDA IND clearance. It marks a decisive step toward synchronized U.S.–China clinical development.”

Further elaborating on their vision, Zhang emphasized the importance of leveraging their innovative InTelliCAR™ platform to broaden the accessibility of transformative therapies for patients worldwide. IASO Bio’s efforts extend beyond IASO208; they maintain a diversified pipeline featuring a total of ten products and product candidates, ensuring comprehensive treatment options across various diseases.

IASO Bio was founded in 2017 and has positioned itself as a leading biopharmaceutical company within China’s Advanced Therapy Medicinal Product sector. The company’s robust platform integrates advanced technologies throughout the lifecycle of product development, from discovery to commercialization. IASO is steadfast in its commitment to providing patients with life-saving therapies based on cutting-edge scientific advancements.

With compelling progress on IASO208 and an exciting pipeline of therapeutic candidates, IASO Bio is poised to bridge the gap between innovative research and practical medical applications. The implications of this synchronized clinical development could very well redefine treatment standards, offering hope to countless patients across the globe as the company strives to bring their China-originated innovations to a wider audience.

As the landscape of biopharmaceuticals continues to evolve, IASO Bio stands at the forefront, ready to tackle the challenges and opportunities of a rapidly advancing therapeutic market. Its endeavors highlight a promising future where innovative treatments can reach patients in need much sooner, especially in the formidable fight against hematologic diseases and beyond.